Active Recombinant Human VEGF165 protein, His-Avi-tagged, Biotinylated

• Cat.No.: VEGF165-562HB
• Product Overview: Biotinylated Recombinant Human VEGF165 protein(Ala 27 - Arg 191), fused with His and Avi tag, was expressed in HEK293.

Specification

• Species: Human
• Source: HEK293
• Tag: His&Avi
• ProteinLength: Ala 27 - Arg 191
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4, 10% trehalose.
• Bio-activity: Immobilized Human VEGF R2, His Tag at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, His,Avitag with a linear range of 2-39 ng/mL. Immobilized Anti-VEGF MAb, Human IgG1 (Avastin) at 5 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, His,Avitag with a linear range of 1-15.6 ng/mL. Immobilized Human VEGF R2, His Tag at 2 μg/mL (100 μL/well), can bind pre-mixed increasing concentrations of Bevacizumab and 0.05 μg/mL (100 μL/well) Biotinylated Human VEGF165, His,Avitag with a half maximal inhibitory concentration (IC50) of 0.74 μg/mL.
• Molecular Mass: This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag).The protein has a calculated MW of 22.4 kDa (monomer). As a result of glycosylation, the protein migrates as 25-33 kDa (monomer) under reducing (R) condition, and 42-55 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >95% as determined by SDS-PAGE.
• Storage: For long term, the product should be stored at lyophilized state at -20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after at:
  -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.